» Articles » PMID: 8855819

Loss of Chromosome Arm 9p DNA and Analysis of the P16 and P15 Cyclin-dependent Kinase Inhibitor Genes in Human Parathyroid Adenomas

Overview
Specialty Endocrinology
Date 1996 Oct 1
PMID 8855819
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Rearrangement and overexpression of the PRAD1/cyclin D1 oncogene, a cell cycle regulator, have been implicated in the pathogenesis of a subset of parathyroid adenomas. Recently, two cell cycle regulators that inhibit the cyclin D1-associated kinases cdk4 and cdk6 have been identified: p16 and p15, the products of the INK4A (also known as CDKN2, MTS1) and INK4B (also known as MTS2) putative tumor suppressor genes located on 9p21. Because inactivation of the p16 or p15 genes might be expected to result in oncogenic consequences similar to those from cyclin D1 overexpression, we examined 25 parathyroid adenomas for 1) allelic loss of polymorphic DNA loci on chromosome arm 9p, 2) homozygous deletions of the p16 and p15 genes by Southern blot analysis, and 3) mutations of the p16 and p15 genes by single strand conformational polymorphism analysis. Heterozygous allelic loss at 9p was observed in 4 of 25 adenomas (16%); their smallest shared region of deletion was 9p21-pter, which includes both the p16 and p15 genes. However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some human cancers, were not found in any parathyroid tumors. These observations indicate that inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas; however, loss of a different tumor suppressor gene (or genes) on 9p appears to contribute to the pathogenesis of a significant percentage of these tumors.

Citing Articles

Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism.

Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto M, Barcons S, Guirao X J Endocrinol Invest. 2022; 46(4):829-840.

PMID: 36334246 PMC: 10023768. DOI: 10.1007/s40618-022-01948-7.


Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.

Arya A, Bhadada S, Singh P, Sachdeva N, Nahar Saikia U, Dahiya D Sci Rep. 2017; 7(1):3123.

PMID: 28600574 PMC: 5466668. DOI: 10.1038/s41598-017-03143-8.


Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.

Costa-Guda J, Soong C, Parekh V, Agarwal S, Arnold A Horm Cancer. 2013; 4(5):301-7.

PMID: 23715670 PMC: 6288794. DOI: 10.1007/s12672-013-0147-9.


The DNA methylome of benign and malignant parathyroid tumors.

Starker L, Svedlund J, Udelsman R, Dralle H, Akerstrom G, Westin G Genes Chromosomes Cancer. 2011; 50(9):735-45.

PMID: 21638518 PMC: 3134609. DOI: 10.1002/gcc.20895.


Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.

Juhlin C, Kiss N, Villablanca A, Haglund F, Nordenstrom J, Hoog A PLoS One. 2010; 5(3):e9472.

PMID: 20208994 PMC: 2830427. DOI: 10.1371/journal.pone.0009472.